Correction: Getinge announces preliminary results for third

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Correction: Getinge announces preliminary results for third quarter 2013

Getinge’s consolidated profit before tax for the third quarter 2013 is expected to amount to 560-570 MSEK, which materially deviates from the expectations indicated by the market consensus estimate. The weaker earnings statement is primarily attributable to the following factors: -          unfavorable product mix within the Critical Care division -          time delay in cost synergies related to the TSS acquisition -          the US Medical Device Tax and negative exchange-rate effects For the full year, the organic volume growth is still expected to exceed last year and amount to approximately 3-4 %. Profit before tax for the full year is estimated to total at 3 000 – 3 200 MSEK including restructuring expenses and other nonrecurring expenses. This announcement will be followed by a conference call at 10.00 AM CET today, hosted by Johan Malmquist, CEO Getinge Group and Ulf Grunander, CFO Getinge Group. Getinge will issue its full Q3 report for 2013 on October 15th at 1:00 PM CET. Conference Call To participate, please call: Sweden: +46 (0)8 5065 3938 UK: +44 (0)20 3427 1905 Passcode: 7592961 Agenda 09.45 Call the conference number 10.00 Introduction 10.10 Q&A 11.00 End of conference A recorded version of the conference will be accessible for five working days at the following number: Sweden: +46 (0)8 5051 3897 UK: +44 (0)20 3427 0598 US: +1 347 366 9565 Passcode: 7592961 For further information, please contact: Johan Malmquist                                                       Ulf Grunander CEO, Getinge Group                                                 CFO, Getinge Group Phone: +46 10 335 55 33                                         Phone: +46 10 335 55 80 Email: johan.malmquist@getinge.com                     Email: ulf.grunander@getinge.com GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care. The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Capricor's Challenges: FDA Review Delays and Legal Woes

Updated Category News Views 21

Capricor Under the Spotlight: FDA and SEC Concerns Ah, Capricor Therapeutics, Inc. (NASDAQ: CAPR)—a tale of high stakes and even higher expectations now hanging by a very taut thread. Investors are feeling the heat as the U.S. Food and Drug Administration (FDA) presses pause on Capricor's plans, and the courtroom drama unfolds with a securities class action looming over...

Continue Reading
La Rosa Holdings Achieves Record Growth with 188% Revenue Surge

Updated Category News Views 144

La Rosa Holdings Reports Impressive Revenue Growth in 2024 Revenue for Q3 2024 Climbs 188% Year-Over-Year to $19.6 Million Aiming for $100 Million in Annualized Revenue by Year-End La Rosa Holdings Corp. (NASDAQ: LRHC) recently disclosed its financial progress, showcasing remarkable growth in the real estate sector. The company revealed that its total revenue witnessed a...

Continue Reading
Navigating the Intricacies of Micron Technology's Options Market

Updated Category News Views 163

Understanding Micron Technology's Market Landscape Investors have recently adopted a bearish stance towards Micron Technology (NASDAQ: MU), a trend that calls for attention among market participants. The sizable options activities we've noticed could hint at significant changes brewing in the market for this semiconductor giant. These insights stem from a comprehensive...

Continue Reading
Viz.ai Unveils New Data Showcasing Stroke Treatment Innovations

Updated Category News Views 288

Viz.ai is cutting through the noise in stroke treatment with its revolutionary technology. They’ve recently unveiled some pretty remarkable clinical data showcasing how their product, Viz LVO, can significantly alter the game for patients dealing with large vessel occlusions—an ischemic stroke that typically spells trouble. This isn’t just another tech story; it’s...

Continue Reading
Linda A. Smith: A Leader in Finance and Budgeting

Updated Category News Views 170

Linda A. Smith Earned Pinnacle Professional Membership Linda A. Smith has made a remarkable mark in the finance sector, and her recent accolade as a Pinnacle Professional Member is a testament to her expertise and commitment. With more than 23 years of experience in finance and budgeting, she brings an impressive array of knowledge and skills to her role. Distinguished...

Continue Reading